1. A method for determining the probability of whether a patient is responsive to treatment with an antagonist VEGF, the method comprising: (a) detecting the expression of at least one gene shown in table 1 or 2, in a biological sample which is obtained from a patient before any administration of the antagonist VEGF patient, and (b) comparing the level of expression of at least one gene to a reference level of expression of at least one gene, where a change in the expression level of at least one gene in a sample from the patient relative to the reference level is identified patient Who are more likely to respond to treatment with an antagonist VEGF.2. A method according to Claim. 1, where the patient enters the patient population to be tested for susceptibility to antagonist VEGF, and the reference level is the average level of expression of at least one gene in patsientov.3 population. A method according to Claim. 1, where the change in expression level of at least one gene in a patient sample is increasing relative to the reference urovnya.4. A method according to Claim. 1, where the change in expression level of at least one gene in a sample from a patient is a decrease relative to a reference urovnya.5. A method according to Claim. 1, where the expression of at least one gene in a biological sample which is obtained in the patient is detected by measuring mRNK.6. A method according to Claim. 1, where the expression of at least one gene in a biological sample which is obtained in the patient is detected by measuring the protein levels in plazme.7. A method according to Claim. 1, wherein the biological sample is a tumor tkan.8. A method according to Claim. 1 further comprising detecting the expression of at least a second gene, referred to in Table 1 or 2, of biological1. Способ определения, с какой вероятностью пациент реагирует на лечение антагонистом VEGF, где способ включает:(a) детекцию экспрессии по меньшей мере одного гена, указанного в таблице 1 или 2, в
